GlassScriptPhysician profile
James Incalcaterra
NPI 1609887082
$3,402.69
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,276 · 2020: $723 · 2021: $201 · 2022: $203.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $628.51 | 2019-2022 | |
| Novo Nordisk INC | $507.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $286.93 | 2019-2020 | |
| Amgen INC. | $235.34 | 2019-2022 | |
| Astellas Pharma US INC | $184.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $183.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.25 | 2019-2021 | |
| Abbvie INC. | $171.43 | 2019-2022 | |
| Pfizer INC. | $146.35 | 2019-2020 | |
| Glaxosmithkline, LLC. | $141.34 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.77 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $68.93 | 2019-2020 | |
| Allergan, INC. | $65.94 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $62.58 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $61.70 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $58.54 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.04 | 2019 | |
| Esperion Therapeutics, INC. | $44.35 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $41.61 | 2019 | |
| Genentech USA, INC. | $40.28 | 2019-2020 | |
| Shire North American Group INC | $34.31 | 2019 | |
| Metuchen Pharmaceuticals | $25.58 | 2019 | |
| Adlon Therapeutics L.P. | $18.15 | 2019 | |
| Eisai INC. | $15.39 | 2019 | |
| Gilead Sciences, INC. | $15.26 | 2019 | |
| Currax Pharmaceuticals LLC | $14.66 | 2021 | |
| Tactile Systems Technology INC | $12.93 | 2019 | |
| Sanofi Pasteur INC. | $10.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Incalcaterra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.